{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:42Z","timestamp":1790404062622,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":561,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Prince Alfred Hospital"},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"Melanoma Foundation of the University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Identifying patients with sentinel node-negative melanoma at high risk of recurrence or death is important. The European Organisation for Research and Treatment of Cancer (EORTC) recently developed a prognostic model including Breslow thickness, ulceration and site of the primary tumour. The aims of the present study were to validate this prognostic model externally and to assess whether it could be improved by adding other prognostic factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with sentinel node-negative cutaneous melanoma were included in this retrospective single-institution study. The \u03b2 values of the EORTC prognostic model were used to predict recurrence-free survival and melanoma-specific survival. The predictive performance was assessed by discrimination (c-index) and calibration. Seeking to improve the performance of the model, additional variables were added to a Cox proportional hazards model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Some 4235 patients with sentinel node-negative cutaneous melanoma were included. The median follow-up time was 50 (i.q.r. 18\u00b75\u201381\u00b75) months. Recurrences and deaths from melanoma numbered 793 (18\u00b77 per cent) and 456 (10\u00b78 per cent) respectively. Validation of the EORTC model showed good calibration for both outcomes, and a c-index of 0\u00b769. The c-index was only marginally improved to 0\u00b771 when other significant prognostic factors (sex, age, tumour type, mitotic rate) were added.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study validated the EORTC prognostic model for recurrence-free and melanoma-specific survival of patients with negative sentinel nodes. The addition of other prognostic factors only improved the model marginally. The validated EORTC model could be used for personalizing follow-up and selecting high-risk patients for trials of adjuvant systemic therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.11262","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T12:56:31Z","timestamp":1563281791000},"page":"1319-1326","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma"],"prefix":"10.1093","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-4131","authenticated-orcid":false,"given":"N A","family":"Ipenburg","sequence":"first","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Department of Dermatology, Leiden University Medical Centre , Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O E","family":"Nieweg","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Centre , Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Scolyer","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Department of Medical Oncology, Royal North Shore Hospital , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-2496","authenticated-orcid":false,"given":"J F","family":"Thompson","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney , Sydney, New South Wales, Australia"},{"name":"Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"S","family":"Lo","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney , Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"2022100812421832300_bjs11262-bib-0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"2022100812421832300_bjs11262-bib-0002","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2022100812421832300_bjs11262-bib-0003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2018.10.060","article-title":"A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy","volume":"80","author":"Bertolli","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022100812421832300_bjs11262-bib-0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1203475417720201","article-title":"Metastatic melanoma in sentinel node-negative patients: the Ottawa experience","volume":"22","author":"Ward","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"2022100812421832300_bjs11262-bib-0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1245\/s10434-016-5566-8","article-title":"Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients","volume":"24","author":"Faut","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0006","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"key":"2022100812421832300_bjs11262-bib-0007","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg"},{"key":"2022100812421832300_bjs11262-bib-0008","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1245\/ASO.2005.03.074","article-title":"Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy","volume":"12","author":"Yee","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0009","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","article-title":"Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma","volume":"16","author":"Gershenwald","year":"1998","journal-title":"J Clin Oncol"},{"key":"2022100812421832300_bjs11262-bib-0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0002-9610(02)01102-9","article-title":"Patterns of early recurrence after sentinel lymph node biopsy for melanoma","volume":"184","author":"Chao","year":"2002","journal-title":"Am J Surg"},{"key":"2022100812421832300_bjs11262-bib-0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/bjs.10995","article-title":"Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes","volume":"106","author":"Verver","year":"2019","journal-title":"Br J Surg"},{"key":"2022100812421832300_bjs11262-bib-0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0000000000000211","article-title":"Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy","volume":"26","author":"O'Connell","year":"2016","journal-title":"Melanoma Res"},{"key":"2022100812421832300_bjs11262-bib-0013","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"2022100812421832300_bjs11262-bib-0014","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2022100812421832300_bjs11262-bib-0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"2022100812421832300_bjs11262-bib-0016","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2022100812421832300_bjs11262-bib-0017","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1245\/s10434-006-9267-6","article-title":"Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes","volume":"14","author":"Zogakis","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0018","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ejso.2016.03.038","article-title":"Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients","volume":"42","author":"Gambichler","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat Med"},{"key":"2022100812421832300_bjs11262-bib-0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10434-001-0538-y","article-title":"The definition of a sentinel node","volume":"8","author":"Nieweg","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0021","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1245\/s10434-011-1988-5","article-title":"Treatment and prognostic significance of positive interval sentinel nodes in patients with primary cutaneous melanoma","volume":"18","author":"Verwer","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jso.21770","article-title":"Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma","volume":"104","author":"Uren","year":"2011","journal-title":"J Surg Oncol"},{"key":"2022100812421832300_bjs11262-bib-0023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.semdp.2008.04.002","article-title":"Pathologic examination of sentinel lymph nodes from melanoma patients","volume":"25","author":"Scolyer","year":"2008","journal-title":"Semin Diagn Pathol"},{"key":"2022100812421832300_bjs11262-bib-0024","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","journal-title":"JAMA"},{"key":"2022100812421832300_bjs11262-bib-0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3322\/caac.21339","article-title":"American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine","volume":"66","author":"Kattan","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2022100812421832300_bjs11262-bib-0026","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","article-title":"Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database","volume":"29","author":"Thompson","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022100812421832300_bjs11262-bib-0027","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.15552","article-title":"Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis","volume":"178","author":"Gualano","year":"2018","journal-title":"Br J Dermatol"},{"key":"2022100812421832300_bjs11262-bib-0028","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/sim.1422","article-title":"Simplifying a prognostic model: a simulation study based on clinical data","volume":"21","author":"Ambler","year":"2002","journal-title":"Stat Med"},{"key":"2022100812421832300_bjs11262-bib-0029","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"2022100812421832300_bjs11262-bib-0030","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022100812421832300_bjs11262-bib-0031","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2002.08.024","article-title":"Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690","volume":"20","author":"Rao","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022100812421832300_bjs11262-bib-0032","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archsurg.1991.01410360031006","article-title":"The prognostic implications of microscopic satellites in patients with clinical stage I melanoma","volume":"126","author":"Le\u00f3n","year":"1991","journal-title":"Arch Surg"},{"key":"2022100812421832300_bjs11262-bib-0033","first-page":"18","article-title":"A global review of melanoma follow-up guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"2022100812421832300_bjs11262-bib-0034","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cup.12969","article-title":"Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma","volume":"44","author":"Moy","year":"2017","journal-title":"J Cutan Pathol"},{"key":"2022100812421832300_bjs11262-bib-0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-11-0490","article-title":"Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma","volume":"18","author":"Xu","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bjs.11262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bjs.11262","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/106\/10\/1319\/46375316\/bjs11262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/106\/10\/1319\/46375316\/bjs11262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T13:00:32Z","timestamp":1665234032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/106\/10\/1319\/6120943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,7,16]]},"published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.11262","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"2019-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}